Nationwide prospective registry database of patients with newly diagnosed untreated pleural mesothelioma in Japan
© 2023 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association..
Due to the scarcity of large-sized prospective databases, the Japanese Joint Committee for Lung Cancer Registry conducted a nationwide prospective registry for newly diagnosed and untreated pleural mesothelioma. All new cases diagnosed pathologically as any subtype of pleural mesothelioma in Japan during the period between April 1, 2017, to March 31, 2019, were included before treatment. Data on survival were collected in April 2021. The eligible 346 patients (285 men [82.3%]; 61 women [17.7%]; median age, 71.0 years [range, 44-88]) were included for analysis. Among these patients, 138 (39.9%) underwent surgery, 164 (47.4%) underwent non-surgical therapy, and the remaining 44 (12.7%) underwent best supportive care. The median overall survival for all 346 patients was 19.0 months. Survival rates at 1, 2, and 3 years for all patients were, 62.8%, 42.3%, and 26.5%, respectively. Median overall survival was significantly different among patients undergoing surgery, non-surgical treatment, and best supportive care (32.2 months vs. 14.0 months vs. 3.8 months, p < 0.001). The median overall survival of patients undergoing pleurectomy/decortication and extrapleural pneumonectomy was 41.8 months and 25.0 months, respectively. Macroscopic complete resection resulted in longer overall survival than R2 resection and partial pleurectomy/exploratory thoracotomy (41.8 months vs. 32.2 months vs. 16.8 months, p < 0.001). Tumor shape, maximum tumor thickness, and sum of three level thickness were significant prognostic factors. The data in the prospective database would serve as a valuable reference for clinical practice and further studies for pleural mesothelioma.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:115 |
|---|---|
| Enthalten in: |
Cancer science - 115(2024), 2 vom: 01. Feb., Seite 507-528 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hasegawa, Seiki [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chemotherapy |
|---|
| Anmerkungen: |
Date Completed 14.02.2024 Date Revised 14.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/cas.16021 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365388343 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365388343 | ||
| 003 | DE-627 | ||
| 005 | 20240214232952.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/cas.16021 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1293.xml |
| 035 | |a (DE-627)NLM365388343 | ||
| 035 | |a (NLM)38047872 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hasegawa, Seiki |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nationwide prospective registry database of patients with newly diagnosed untreated pleural mesothelioma in Japan |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2024 | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. | ||
| 520 | |a Due to the scarcity of large-sized prospective databases, the Japanese Joint Committee for Lung Cancer Registry conducted a nationwide prospective registry for newly diagnosed and untreated pleural mesothelioma. All new cases diagnosed pathologically as any subtype of pleural mesothelioma in Japan during the period between April 1, 2017, to March 31, 2019, were included before treatment. Data on survival were collected in April 2021. The eligible 346 patients (285 men [82.3%]; 61 women [17.7%]; median age, 71.0 years [range, 44-88]) were included for analysis. Among these patients, 138 (39.9%) underwent surgery, 164 (47.4%) underwent non-surgical therapy, and the remaining 44 (12.7%) underwent best supportive care. The median overall survival for all 346 patients was 19.0 months. Survival rates at 1, 2, and 3 years for all patients were, 62.8%, 42.3%, and 26.5%, respectively. Median overall survival was significantly different among patients undergoing surgery, non-surgical treatment, and best supportive care (32.2 months vs. 14.0 months vs. 3.8 months, p < 0.001). The median overall survival of patients undergoing pleurectomy/decortication and extrapleural pneumonectomy was 41.8 months and 25.0 months, respectively. Macroscopic complete resection resulted in longer overall survival than R2 resection and partial pleurectomy/exploratory thoracotomy (41.8 months vs. 32.2 months vs. 16.8 months, p < 0.001). Tumor shape, maximum tumor thickness, and sum of three level thickness were significant prognostic factors. The data in the prospective database would serve as a valuable reference for clinical practice and further studies for pleural mesothelioma | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a chemotherapy | |
| 650 | 4 | |a database | |
| 650 | 4 | |a pleural mesothelioma | |
| 650 | 4 | |a staging system | |
| 650 | 4 | |a surgery | |
| 700 | 1 | |a Shintani, Yasushi |e verfasserin |4 aut | |
| 700 | 1 | |a Takuwa, Teruhisa |e verfasserin |4 aut | |
| 700 | 1 | |a Aoe, Keisuke |e verfasserin |4 aut | |
| 700 | 1 | |a Kato, Katsuya |e verfasserin |4 aut | |
| 700 | 1 | |a Fujimoto, Nobukazu |e verfasserin |4 aut | |
| 700 | 1 | |a Hida, Yasuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Morise, Masahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Moriya, Yasumitsu |e verfasserin |4 aut | |
| 700 | 1 | |a Morohoshi, Takao |e verfasserin |4 aut | |
| 700 | 1 | |a Suzuki, Hidemi |e verfasserin |4 aut | |
| 700 | 1 | |a Chida, Masayuki |e verfasserin |4 aut | |
| 700 | 1 | |a Endo, Shunsuke |e verfasserin |4 aut | |
| 700 | 1 | |a Kadokura, Mitsutaka |e verfasserin |4 aut | |
| 700 | 1 | |a Okumura, Meinoshin |e verfasserin |4 aut | |
| 700 | 1 | |a Hattori, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Date, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshino, Ichiro |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer science |d 2003 |g 115(2024), 2 vom: 01. Feb., Seite 507-528 |w (DE-627)NLM12479498X |x 1349-7006 |7 nnns |
| 773 | 1 | 8 | |g volume:115 |g year:2024 |g number:2 |g day:01 |g month:02 |g pages:507-528 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/cas.16021 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 115 |j 2024 |e 2 |b 01 |c 02 |h 507-528 | ||